Reactions of sera from healthy blood donors to smooth and rough mutant lipopolysaccharides (LPS) from Escherichia coli 0111:B4 and Salmonella minnesota which had been complexed with polymyxin B were determined by enzyme-linked immunosorbent assay. Relative enzyme-linked immunosorbent assay reactivities were examined for prima facie evidence of cross-reactivity by analyses of correlation and relative scatter. Patterns of reactivity were interpreted in relation to published structures. Evidence was obtained for two dominant epitopes associated with the lipid A-2-keto-3-deoxyoctulosonic acid and heptose regions of the LPS core. Sera demonstrated apparent exclusive antibody homogeneity in that given sera showed only one of the two possible specificities, which occurred with equal frequency. Cross-reactivity was found in the lipid A-2-keto-3-deoxyoctulosonic acid region for all LPS. Cross-reactivity was found in the heptose region for larger rough mutant S. minnesota LPS and smooth S. minnesota LPS and for E. coli 0O111:B4 LPS but not for E. coli rough mutant J5 LPS, whose heptose region appears to be different from those of the other organisms.
High mortality has continued to accompany gram-negative bacteremia and septic shock despite the introduction of new antibiotics and improved patient care (7, 15, 16) . Recently, a number of investigators have attempted to demonstrate the potential of passive immunotherapy in sepsis by employing antibodies to gram-negative bacterial endotoxin (lipopolysaccharide [LPSI), the principal agent responsible for the pathophysiological features of septic shock (32) . The strategies employed, which have been reviewed elsewhere (5, 33) , have consisted principally of (i) employing immune plasma from volunteers, e.g., those immunized with polyvalent (Pseudomonas) 0 serotype LPS vaccine (14) or with rough mutant bacteria lacking any 0 serotype LPS polysaccharide and expressing only the common core glycolipid (CGL) region of the LPS molecule (1) or (ii) employing plasma from selected blood donors with high titers of natural antibody, e.g., antibodies to a "cocktail' of smooth LPS from 12 different gram-negative bacteria (17) or with high titers of antibody to lipid A (19) . In all cases but the CGL-immune plasma, which was used whole, immunoglobulin fractions were extracted from plasma for therapeutic use. Immunoglobulin G (IgG) fractions were used, except for the anti-lipid A plasma, from which a fraction including both IgG and IgM was used. In each case, some clinical benefit was demonstrable. However, the basis for the protection remains unclear, since the full range of anti-LPS antibodies to specific or cross-reactive LPS structures in the preparations employed for therapy, as well as their relative contributions to different clinical aspects of gram-negative bacteremia and septic shock, has not been defined (5) .
Standard characterized preparations of LPS are not available, and the effects of structural microheterogeneity on the antigenicity and cross-reactivity of the LPS CGL region are not known. Clinical and laboratory studies of anti-CGL antibodies have employed predominantly either the structur-* Corresponding author.
ally well-characterized rough (R) mutant series of Salmonella LPS (Ra to Re) or the less-well-characterized Escherichia coli 0111:B4 rough mutant J5, often taken to be equivalent to the Salmonella Rc LPS (see Discussion). Antibodies to Salmonella Re LPS (20, 29) and to E. coli J5 LPS (6, 18, 29) have been studied in normal (18, 29) and clinical (6, 20) sera. Evidence was found that autologous anti-R-LPS antibodies are clinically beneficial; it has also been reported that anti-LPS antibodies against LPS from smooth organisms as antigen are clinically beneficial (9) . It is not clear how these studies relate to each other, since the degree of cross-reactivity of natural antibodies in human sera with these different LPS antigens has not been characterized. Neither is it clear which, if any, of the different R-LPS available represents an optimal structure for use as antigen in evaluating human serum for potential therapeutic antibody content. As a preliminary study to assess the frequencies and possible interrelationships of natural IgG antibodies to Salmonella and E. coli LPS CGL in a blood donor population, to evaluate availability of such antibodies, and to identify serological characteristics for further investigations of the relative potential of different donors' natural antibodies for intravenous IgG administration (12, 21) for therapy of septic shock, we screened 763 blood donor sera for antibodies to smooth and rough mutant Salmonella minnesota (Ra, Rc, and Re) LPS and to LPS from E. coli 0111:B4 and its rough mutant J5. We employed an enzymelinked immunosorbent assay (ELISA) screening method based on LPS complexed with polymyxin B which we have shown (27) to be superior to methods previously described for measuring CGL-specific antibodies.
MATERIALS AND METHODS
ELISA for human IgG anti-LPS antibodies. The ELISA for human IgG anti-LPS antibodies was carried out essentially as previously described (27) (Ec-J5  LPS) , and of smooth S. minnesota (Sm-0 LPS) and three of its rough mutants, Ra (Sm-Ra LPS), Rc (Sm-Rc LPS), and Re (Sm-Re LPS). Polymyxin B sulfate (Sigma Chemical Co., St. Louis, Mo.) (1 mg/ml) and LPS (10 ,ug/ml) were complexed as previously described (27) . After dialysis, the polymyxin-LPS complexes were diluted further (1:16) Fig. 1D and Discussion). The sera identified in this way (see Fig. 1D However, the scatter also shows that some sera showed higher reactivities with the complete, smooth Sm-0 LPS. In the Sm-Ra-Sm-Rc pairing (Fig. 1C) , the slope (0.76) was closer to unity but still indicated greater reactivity overall with the smaller Sm-Rc LPS. For these two LPS antigens, the scatter distribution was more compact and was close to the cross-reactive diagonal, indicating nearly equivalent antigenicity for the antibodies in these 763 sera.
When Sm-0, Sm-Ra and Sm-Rc LPS were plotted against Sm-Re LPS, the OD scatter for the 763 sera was bimodal ( Fig. 1D to F) Fig. 1D . This convention helped us to trace the movement of sera from these particular two groups when other pairs of antigens were plotted (Fig. 1A to 0) .
It was found that, in the Sm-Ra-Sm-Re and Sm-Rc-Sm-Re pairs, the same cross-reactive sera (cross) from the Sm-0-Sm-Re pair remained distributed along the x-y diagonal, indicating cross-reactivity, and that the same single-antigenreactive sera (open circles) still segregated closer to the y axis ( Fig. 1E and F) . As the y axis LPS decreased in size, the scatter distribution of the cross-reactive (cross) serum group migrated closer to the x-y diagonal such that it lay along it for the Sm-Rc-Sm-Re pair (slope = 1.02 for regression of the cross-reactive sera alone; Fig. 1F ). In the pairings of the larger three Salmonella LPS (Fig. 1A to C) , the crossreactive and single-antigen-reactive serum groups were homogeneously distributed.
(ii) Distribution of ELISA serum reactivities to smooth E. coli 0111 LPS relative to those to S. minnesota smooth and rough mutant LPS. When the Salmonella Re LPS were compared with the smooth E. coli 0111 LPS (Fig. 1G) (Fig. 1H and I) . Here, the cross-reactive group (cross) showed a distribution similar to that found in Fig. 1G, on or below the x-y diagonal; however, the single-antigen-reactive group (open circle) of Fig. 1G now began to show crossreactivity, moving away from the y axis towards the x-y diagonal. When smooth S. minnesota Sm-0 LPS was compared with smooth E. coli Ec-O111 LPS (Fig. 1J) , there was no evidence of bimodality. The sequence of distributions in Fig. 1G to J can be seen as a gradual change from bimodality to unimodality, with increasing size of the Salmonella LPS compared with the smooth. E. coli LPS as ELISA antigens, reflecting increasing cross-reactivity between the Salmonella LPS and the smooth E. coli LPS of the single-antigenreactive group of sera (open circle), converging with the cross-reactive group (cross). In the Ec-0111-Sm-0 LPS pairing, sera tended to react more strongly with Ec-G111 LPS than with Sm-0 LPS, and the most strongly reactive sera were predominantly from the single-antigen-reactive group (open circles, Fig. 1 ).
(iii) Relative distributions of ELISA serum reactivities to smooth E. coli 0111 LPS and to LPS from its rough mutant J5. In comparison of smooth E. coli Ec-G111 LPS and E. coli rough mutant Ec-J5 LPS as antigens in ELISA, a distinct bimodal pattern was found (Fig. 1K) Fig. 1L to 0) . The distributions of the main groups indicated, as in the other cases, cross-reactivity (cross) on the x-y diagonal and singleantigen reactivity on the y axis (Ec-illl axis). The general distribution of these main serum groups resembled most closely that of the Ec-0111-Sm-Re pairing (Fig. 1G) , but the single-antigen-reactive sera (open circles) in the Ec-0111-Ec-J5 pairing showed more tendency to move out from the y axis, indicating some cross-reactivity between Ec-0111 and Ec-J5.
(iv) Distribution of ELISA serum reactivities to E. coli rough mutant J5 LPS relative to those to S. miianesota smooth and rough mutant LPS. In the pairing of Ec-J5 with Sm-G, Sm-Ra, and Sm-Rc, the distribution of the relative scatter of ELISA reactivities of the majority of the 763 sera was unimodal, with no segregationl of the indicated sera (open circles and crosses); however, a minor subgroup of 14 sera segregated out, with strong anti-J5 reactivity (Fig. 1L to N) . The overall pattern was essentially the same for the Ec-J5-Sm-Re pairing (Fig. 10) , except that, in general, sera showing the most reactivity with either antigen were predominantly from the cross-reactive group (crosses), and these sera tended to show more reactivity with Sm-Re than with Ec-J5.
DISCUSSION
Several facets of the results of this investigation need to be considered together. This is necessary to arrive at a hypothesis which can provide an overall interpretation. First, and unexpectedly, we found that in certain antigen pairings the scatter of reactivities tended to segregate into two groups. Second, it was found that where this bimodal distribution occurred the same sera segregated together into distinct groups (indicated by open circles and crosses; Fig. 1A to G). Third, it was possible to interpret the segregation of reactivities to take into account differences in the structures of the LPS molecules, as demonstrated below. Fourth, this interpretation is possible only if the reactivities found represent antibody populations which are substantially homogeneous in specificity for LPS CGL in any given serum, exhibiting predominance of specificity for only one out of a number of possible epitopes represented on the CGL.
As we found previously (27) , analysis of correlation is of limited value in such an investigation. All of the antigens, when paired with each other, showed a degree of correlation which was significant at the P < 1% level (Table 1) , indicating some degree of positive association for all but the Ec-0111-Sm-Re pairing, which had a negative correlation. However, a much more explicit interpretation of the relative reactivities of serum IgG antibodies with these LPS antigens was provided by the plots of the relative scatter of reactivities (OD absorbances) to each pair of antigens (Fig. IA to   G ). This analysis of ELISA data is comparable to previously used passive hemagglutination methods for investigation of serological cross-reactivity of rough mutant LPS cores (26) but appears amenable to more-detailed interpretation, especially in relation to LPS CGL structure.
The structures of the LPS used as antigens in this study can be represented schematically as shown in Table 2 (10, 28) suggested the structure for Ec-J5 LPS shown in Table 2 , in which the glucosamine is probably N acetylated (28) . This structure appears to have a heptose region substantially different from that taken to be the representative structure of the Enterobacteriaceae (13) , and it is difficult to envisage how this structure could be derived from the parental Ec-0111 LPS by mutation to loss of UDPgalactose-epimerase activity (failure to insert the galactose core moiety) as the only mutation leading to the LPS of E. coli J5. However, Stein and Heath (28) suggest that the heptose region represented for the J5 mutant, with Nacetylglucosamine linked to heptose of the LPS core, is a general feature of E. coli 0111:B4 and its rough mutants which retain heptose in their LPS, which would mean that the structure of Ec-0111 LPS differs from that shown in Table 2 . This anomaly may be resolved by the suggestion by Morrison and Leive (23) that the E. coli 0111 LPS is heterogeneous, with at least three variants occurring with different heptose regions (Table 3 ), in which case the E. coli J5 putative structure could be derived from E. coli 0111 LPS structure 3 (Table 3 ). It is possible that E. coli J5 LPS is also heterogeneous in its heptose region, as follows: (i) Glc-Hep (-Hep)-Hep-KDO, (ii) Glc-Hep-Hep-KDO, (iii) Glc-Hep (-GlcNAc-Glc)-Hep-KDO, and that it contains all three heptose regions derivable from parental E. coli 0111 LPS heterogeneity (10) .
The relative scatter of the IgG ELISA results in our study can be interpreted in relation to the known structures. Thus, Sm-G, Sm-Ra, and Sm-Rc LPS behave virtually as identical antigens (Fig. IA to C) , suggesting that there is no significant discrete serum subgroup with antibodies to S. minnesota G polysaccharide or outer core epitopes found in Sm-G or Sm-Ra but not in Sm-Rc and that the majority of sera behave as if the epitopes of these Salmonella LPS molecules located within the heptose-KDO-lipid A inner core region effectively account for almost all anti-Salmonella LPS IgG antibody reactivity in a "naturally immune'" human population. The slopes of the regression lines point to the fact that overall there is stronger reactivity for the smaller LPS of each pair, to which steric hindrance in the larger LPS may contribute.
The bimodal scatter pattern found when the larger (Sm-G, Sm-Ra, and Sm-Rc) Salmonella LPS antigens are compared by ELISA with the small Salmonella Re LPS antigen (Fig.  1D to F) further indicates that approximately one-half of the sera (46.9%) contain antibodies which react with epitopes on the Sm-Re LPS which are also expressed on the larger Salmonella LPS molecules (marked with crosses from Fig.  1D ), while the remaining sera (53.1%) behave as if they contain antibodies to epitopes found on the larger LPS but not on the small Salmnonella Re LPS (marked with open circles from Fig. 1D) . The difference between LPS structures which appears to account for the difference in serology is the phosphorylated tetrasaccharide, comprised of three heptoses and one glucose, which is added to the Re LPS to yield the Rc LPS structure (Table 2) . Thus, it appears that the sera represented by open circles contain only antibodies specific for epitopes on this heptose region (not Re crossreactive), while the sera represented by crosses contain only antibodies to epitopes in the KDO-lipid A region represented by the Salmonella Re LPS. We have adopted the convention of referring to the former sera as the anti-HEP family of antibodies and to the latter sera as the anti-KDO family of antibodies. This convention is for convenience in referring to sera with particular reaction patterns and is not serologically GIcNAc, N-acetylglucosamine; Glc, glucose, Gal, galactose, Hep, heptose. P represents organic phosphorus strict, since the precise specific antibody components of these polyclonal sera remain to be characterized by absorption and inhibition studies of selected sera.
In general, the ELISA scatter reactivity relationships between the smooth E. coli 0111 LPS and the different S. minnesota LPS in terms of the anti-KDO (represented by crosses) and anti-HEP (represented by open circles) serum families appear to be governed by the same rules relating the proposed structures (Table 2) to the scatter of ELISA reactivities (Fig. 1G to J) as were found to apply to the Salmonella LPS, with the same sera showing segregation into discrete groups. This appears to confirm that E. coli 0111 LPS shares both KDO-lipid A region (KDO family) and heptose region (HEP family) cross-reactive sites with the S. minnesota LPS. Two differences were noted. First, the anti-HEP family of sera reacted more strongly with the E. coli 0111 LPS than with the heptose-containing Salmonella LPS, possibly indicating additional prevalence of antibodies at sites on E. coli 0111 LPS except the region sharing cross-reactivity with Salmonella LPS (e.g., R3 outer core or 0111 type-specific polysaccharide). Thus, the anti-HEP serum family distributions remained distinct from the anti-KDO distributions in the Ec-0111-Sm-Rc and Ec-0111-SmRa pairings (Fig. 1H and I) . The effect appears to be associated with the anti-HEP serum family, since it does not appear to disturb the anti-KDO serum family distributions (Fig. 1G to J) . Second, a wider range of cross-reactivity was found in the anti-KDO serum family, with some sera reacting more strongly with the KDO region of the Salmonella R LPS than with the E. coli 0111 LPS. This may have been steric Ec-J5 VOL. 55, 1987 on November 6, 2017 by guest http://iai.asm.org/ Table 2 , footnote a.
hindrance by the large type-specific 0 polysaccharide, since the anti-KDO serum family distribution was less diffuse when both smooth LPS were compared (Fig. J) , where steric hindrance could have operated to an equivalent extent. In the smooth E. coli 0111 LPS and rough mutant J5 LPS pairing (Fig. 1K) , the scatter pattern resembles that of the Ec-0111-Sm-Re pairing (Fig. 1F); i.e., Ec-J5 LPS appears to behave generally similarly to Sm-Re LPS. However, the anti-KDO serum family distribution (represented by crosses) is less diffuse than when the E. /oli 0111 LPS was compared with the Salmonella LPS and lies close to the equivalence diagonal, indicating greater intraspecies correspondence of cross-reactive epitopes. Within the anti-HEP family (repre- sented by open circles), the pattern of high reactivity with smooth LPS and low reactivity with rough mutant LPS is still clearly evident, but there is a trend to show increasing migration away from the y axis (Ec-0111 axis) towards cross-reactivity as the strength of anti-Ec-0111 reactivity increases, perhaps indicating retention of some crossreactivity in some anti-HEP family sera. Taking into account the preceding interpretations, it would appear that the E. coli J5 LPS heptose region is much less cross-reactive (than the Salmonella heptose region) with its parental E. coli 0111 LPS heptose region, reflecting the structures indicated (Table 2), and it may be that the E. coli J5 LPS heptose region is predominantly of the N-acetylglucosamine-linked diheptose type (structure 3, described above), while the E. coli 0111 LPS is predominantly of the triheptose type (structure 1, Table 3 ), similar to that of Salmonella LPS ( Table 2 ).
The scatter patterns of the E. coli J5 LPS pairings with the Salmonella rough mutant LPS (Fig. 1L to 0) confirm that the E. coli J5 LPS is not serologically identical to the Salmonella Re LPS (compare Fig. 1D with F) . Within the anti-HEP serum family, some Salmonella LPS-reactive sera retain some cross-reactivity with J5 LPS, perhaps reflecting heterogeneity of J5 LPS, while within the anti-KDO serum family a number of sera react less well with the E. coli J5 LPS than with the Salmonella LPS, as was found with the parental E. coli 0111 LPS. This can be seen most clearly in the Sm-Re-Ec-J5 pairing (Fig. 10) , in which reactions of the anti-HEP serum family to either LPS are minimal and do not obscure the effect. The scatter here (Fig. 10) , in which only the KDO serum family shows substantial binding, affirms that the CGL lipid A-KDO region is the predominant crossreactive epitope in E. coli J5 LPS.
In all of the plots of ELISA reactivities involving E. coli J5 LPS (Fig. 1K to 0) , a small subgroup of sera (14 out of 763) was found with high anti-J5 LPS reactivity, which was distributed away from the other sera, at the x axis (Ec-J5 axis) maximum. This can be taken as evidence for a distinct epitope found on the J5 LPS but not on the other LPS studied. A good candidate for such an epitope would be the terminal heptose structure of the J5 LPS. Since antibodies of this type occur in 2% of sera from a naturally immune population, this epitope must be encountered in nature. It has been reported (2) that in anti-E. coli J5 immune rabbit serum both J5-LPS-specific and Re-LPS-cross-reactive antibodies occur and that the J5 LPS-specific component may be dominant. This emphasizes the need for careful evaluation of cross-reactive and immunogen-specific components in any immune serum. In J5-LPS-immune sera, if only anti-J5 LPS antibody activities are determined, the J5-LPS-specific component could give a falsely high impression of crossreactivity and could explain why some of the studies of the protective properties of J5 immune sera have been inconclusive (30) . It would appear, from the uncertainty as to the structure of E. coli J5 LPS and the immunogenicity of its unique heptose terminal structure, that E. coli J5 LPS is in many ways an inappropriate antigen to use for such studies.
Our previous studies (27) and extensive unpublished investigations suggest that LPS CGL-polymyxin complex is a more relevant antigen than LPS CGL alone for identification of natural cross-reactive anti-gram-negative LPS sera. Our preliminary evidence indicates that the form in which LPS CGL is presented as antigen is crucially important, both in direct immunoassay for detection of antibody binding and in absorption and inhibition studies. Polymyxin B may complex with LPS in such a way as to present the CGL antigens as they occur in natural (bacterial or host) protein-LPS complexes (22, 25, 31) and may confer structural stability on the LPS (24) . It is probable that purified self-aggregated R-LPS is not a natural antigen. This is the subject of complementary current investigations by us for systematic characterization of human serum antibodies and monoclonal antibodies. The polymyxin-LPS ELISA has, in our hands, improved the resolution of anti-LPS CGL serology so that the relationships described above within natural immunity in a healthy human population have become evident. These relationships are now being subjected to verification in selected sera by antigen absorption and inhibition analysis and will be investigated in competition studies using mouse monoclonal antibodies of defined specificities. Although such studies have proved complex and appear to reflect secondary and tertiary structural effects on LPS epitope expression, preliminary findings support the interpretation of the serological observations reported here.
A working hypothesis for further investigation is that human sera fall into two classes with respect to their anti-CGL antibodies. We had not anticipated this discrete biphasic pattern in "natural" polyclonal sera, but this prima facie pattern of exclusive antibody homogeneity has contributed in a major way to our interpretation of the serology in relation to LPS CGL structure. Natural immunity to crossreactive antigens in the CGL region of LPS arises by exposure to gram-negative bacteria and their endotoxins throughout life. It would be expected that type-specific antibodies and other specific antibodies would fluctuate on the basis of the most recent exposure to LPS, while crossreactive antibody responses are probably anamnestic responses to conserved structures not affected by microheterogeneity. It is not clear whether this phenomenon of apparent exclusive antibody homogeneity is a reflection of the original antigenic sin (11) phenomenon, whether it is a reflection of genetic determinants such as immune response genes, whether it is related to blood groups, or whether it merely reflects the nature of the LPS to which an individual was most recently exposed. Neither is it clear whether the specificity repertoire of "natural" anti-LPS CGL antibodies differs characteristically from that of antibodies (including monoclonal antibodies) raised by immunization with rough strains of gram-negative bacteria or their LPS. We are undertaking longitudinal population serology studies (in relation to collection of high-titer anti-CGL sera for therapeutic IgG preparation) and animal immunization studies to evaluate this phenomenon by using a greatly extended panel of smooth and rough strains of gram-negative bacteria and purified LPS extracts.
